Delayed hematologic toxicity after BCMA–directed CAR T-cell therapy
| Delayed hematologic toxicity day 30-365 . | BCMA–directed CAR T-cell therapy (N = 99) . |
|---|---|
| Neutropenia, n (%) | |
| Severe neutropenia (ANC ≤ 500 cells/uL) | 18 (18) |
| Moderate neutropenia (ANC ≤1000 and >500 cells/uL) | 45 (45) |
| Moderate neutropenia or receipt of granulocyte colony-stimulating factor | 57 (58) |
| T-cell depletion, n (%) | |
| CD4 T-cell count ≤200 cells/uL | 29 (29) |
| Hypogammaglobulinemia | |
| IgG ≤400 mg/dL, n (%) | 69 (70) |
| 3mo IgG, median (range) | 373 (51-7506) |
| 6mo IgG, median (range) | 504 (55-3346) |
| IVIG administration, n (%) | 62 (63) |
| Delayed hematologic toxicity day 30-365 . | BCMA–directed CAR T-cell therapy (N = 99) . |
|---|---|
| Neutropenia, n (%) | |
| Severe neutropenia (ANC ≤ 500 cells/uL) | 18 (18) |
| Moderate neutropenia (ANC ≤1000 and >500 cells/uL) | 45 (45) |
| Moderate neutropenia or receipt of granulocyte colony-stimulating factor | 57 (58) |
| T-cell depletion, n (%) | |
| CD4 T-cell count ≤200 cells/uL | 29 (29) |
| Hypogammaglobulinemia | |
| IgG ≤400 mg/dL, n (%) | 69 (70) |
| 3mo IgG, median (range) | 373 (51-7506) |
| 6mo IgG, median (range) | 504 (55-3346) |
| IVIG administration, n (%) | 62 (63) |